MedTrace Logo

Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

NCT03807921 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2022-03-08

No results posted yet for this study

Summary

This study evaluates the clinical and hemodynamic outcome in patients after aortic valve replacement. Half of the patients will receive warfarin + aspirin and the other half will receive only aspirin. The investigators will focus mainly on early bioprosthesis degeneration.

Conditions

  • Aortic Valve Stenosis
  • Aortic Valve Disease
  • Aortic Valve Insufficiency
  • Aortic Valve Regurgitation

Interventions

DRUG

Warfarin

Oral anticoagulation

DRUG

Aspirin

Antiplatelet treatment

Sponsors & Collaborators

  • Universidad de la Republica

    collaborator OTHER

  • Instituto Nacional de Cirugia Cardiaca, Uruguay

    lead OTHER

Principal Investigators

  • Victor Dayan, MD, PhD · Instituto Nacional de Cirugia Cardiaca

  • Diego Freire, MD · Centro Cardiovascular Universitario

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-12-30
Completion
2019-12-31

Countries

  • Uruguay

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03807921 on ClinicalTrials.gov